Metoprolol Medreg (Metoprolol Tartrate)

Metoprolol Medreg is a selective β1‑adrenergic antagonist used in cardiovascular disease management.

• Hypertension: lowers systolic and diastolic pressure by reducing cardiac output and renin release.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Myocardial infarction: improves survival by limiting infarct size and preventing recurrent ischemia.
• Heart failure: enhances left‑ventricular function and reduces hospitalisation risk.
• Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

• Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in cardiac tissue, diminishing sympathetic stimulation. This reduces heart rate, myocardial contractility, and renin‑angiotensin activation, leading to lower cardiac output and blood pressure while decreasing myocardial oxygen consumption.

Metoprolol Medreg may cause a range of adverse reactions.

Common Side Effects

• Fatigue or general weakness
• Dizziness or light‑headedness
• Bradycardia (slow heart rate)
• Cold extremities
• Gastrointestinal discomfort such as nausea
• Headache

Serious or Rare Side Effects

• Severe bradycardia or heart block
• Marked hypotension
• Bronchospasm, especially in patients with asthma
• Allergic reactions including rash or angioedema
• Depression or mood changes
• Worsening heart failure symptoms

Before initiating therapy, clinicians should consider several safety measures.

• Monitor blood pressure: check regularly to avoid excessive hypotension.
• Assess heart rate: ensure rate remains within safe limits, especially in patients with conduction disease.
• Use caution in asthma or chronic obstructive pulmonary disease: β1 selectivity may not fully prevent bronchospasm.
• Adjust dose in renal impairment: reduced clearance may increase drug exposure.
• Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Metoprolol Tartrate can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Verapamil or diltiazem: additive negative‑chronotropic effect may cause severe bradycardia.
• Class IA or III anti‑arrhythmics (e.g., quinidine, amiodarone): risk of profound conduction disturbances.
• Clonidine abrupt withdrawal: may precipitate hypertensive crisis when combined.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance hypotensive response.
• Diuretics: combined effect on blood pressure and electrolyte balance.
• NSAIDs: can blunt antihypertensive effect.
• Antidiabetic agents: may mask hypoglycaemia symptoms.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase metoprolol plasma levels.